初始乌帕替尼或阿达木单抗治疗对类风湿关节炎患者实现48周治疗目标的影响:SELECT-COMPARE的事后分析
SELECT-COMPARE事后分析评估甲氨蝶呤应答不足的类风湿关节炎患者起始乌帕替尼15 mg每日一次或阿达木单抗40 mg的48周结局。随机分配至两药的患者多数终点达标率相似,但初始乌帕替尼组更快达到治疗目标且处于临床目标的时间更长。
要点
- 起始乌帕替尼或阿达木单抗治疗48周时CDAI缓解/LDA和DAS28(CRP)<2.6/≤3.2达标率相似。
- 初始乌帕替尼组达到DAS28(CRP)<2.6/≤3.2的中位时间比初始阿达木单抗组早6-8周。
- 初始乌帕替尼组在多数临床和患者报告结局上处于较低疾病状态的总时间更长。
核心结论
- 按改良达标治疗策略,无论起始乌帕替尼还是阿达木单抗,48周时CDAI缓解/LDA和DAS28(CRP)<2.6/≤3.2达标率相似。
- 初始接受乌帕替尼的患者更快达到治疗目标,且在最初48周治疗中处于临床目标的时间更长。
研究设计与样本
- SELECT-COMPARE事后分析,患者随机分配至乌帕替尼15 mg每日一次、安慰剂或阿达木单抗40 mg。
- 按方案,第14、18、22周压痛或肿胀关节计数改善<20%或第26周未达到CDAI低疾病活动度者,盲法从乌帕替尼换至阿达木单抗或反之。
- 分析纳入初始随机至乌帕替尼的651例患者(其中252例换至阿达木单抗)和初始随机至阿达木单抗的327例患者(其中159例换至乌帕替尼)。
- 数据按初始随机分组分析,不考虑后续治疗切换。
- 评估至48周的临床缓解/LDA、身体功能、疼痛及新型深度缓解复合终点,并确定相应时间平均应答率。
主要发现
- 第48周时,随机分配至任一治疗的患者在多数治疗终点上达标情况相似。
- 至48周,初始乌帕替尼组在多数临床和患者报告结局上处于较低疾病状态的总时间改善大于初始阿达木单抗组。
- 初始乌帕替尼组达到DAS28(CRP)<2.6/≤3.2的中位时间比初始阿达木单抗组早6-8周。
关键数值与推荐
- 第14、18、22周压痛或肿胀关节计数改善<20%为盲法切换标准之一。
- 第26周未达到CDAI低疾病活动度为盲法切换标准之一。
- 第48周CDAI缓解/LDA和DAS28(CRP)<2.6/≤3.2达标率在初始乌帕替尼与初始阿达木单抗组间相似。
- 初始乌帕替尼组达到DAS28(CRP)<2.6/≤3.2的中位时间比初始阿达木单抗组早6-8周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Evaluate the importance of treatment sequencing in SELECT-COMPARE, assessing potential differences between starting upadacitinib or adalimumab therapy following inadequate MTX response. METHODS: Patients from SELECT-COMPARE were randomized to upadacitinib 15 mg once daily, placebo or adalimumab 40 mg. Per protocol, patients with <20% improvement in tender or swollen joint counts (weeks 14, 18, 22) or failure to achieve Clinical Disease Activity Index (CDAI) low disease activity (LDA) at week 26 were blindly switched from upadacitinib to adalimumab or vice versa. Treatment outcomes, including clinical remission/LDA, physical function, pain and a novel combined endpoint for deep response, were evaluated through 48 weeks and corresponding time-averaged response rates determined. Data were analysed by initial randomized group regardless of any subsequent switch in therapy. RESULTS: This post hoc analysis included 651 patients initially randomized to upadacitinib (of whom 252 switched to adalimumab) and 327 patients initially randomized to adalimumab (of whom 159 switched to upadacitinib). At week 48, patients randomized to either therapy demonstrated similar achievement of most treatment endpoints. Greater improvements in the total time spent in a lower disease state were observed for initial upadacitinib vs initial adalimumab therapy across most clinical and patient-reported outcomes through 48 weeks, and the median time to DAS28(CRP) <2.6/≤3.2 occurred 6-8 weeks earlier among those randomized to upadacitinib. CONCLUSION: Following a modified treat-to-target strategy, rates of CDAI remission/LDA and DAS28(CRP) <2.6/≤3.2 at 48 weeks were similar, regardless of starting therapy. However, patients initially receiving upadacitinib reached treatment targets more quickly and spent more time in clinical targets over the initial 48 weeks of treatment. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02629159.
引用
- Mysler E, Tanaka Y, Kavanaugh A, et al. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE. Rheumatology (Oxford). 2023. PMID: 36018230. doi:10.1093/rheumatology/keac477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。